Helping Your Research
Targeted Content for Cancer Biology
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.
Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).
How it Works
The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.
- Curated content designed for immuno-oncology research
- Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
- Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
- Compatible with RNAscope® and antibody morphology markers for tissue imaging
- Customizable with up to 10 additional targets of interest
- For use with nCounter readout and compatible with DSP Data Center
Curated Content for Immuno-Oncology
The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.
- Profile the global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity
- Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade
Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.
Mapping the Immune Cell Microenvironment with Spatial Profiling in Muscle Tissue Injected with the Venom of Daboia russelii.
Pathological and inflammatory events in muscle after the injection of snake venoms vary in different regions of the affected tissue and at different time intervals. In order to study such heterogeneity in the immune cell microenvironment, a murine model of muscle necrosis based on the injection of the venom of Daboia russelii was used.
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective data are limited.
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA.
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed a unique cohort of 8 melanoma samples with focal loss of PTEN protein expression to understand features and mechanisms of PTEN loss in this disease.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.